豬疫苗市場機會、成長促進因素、產業趨勢分析及預測（2025-2034年）

2024 年全球豬疫苗市場價值為 15 億美元，預計到 2034 年將以 6.1% 的複合年成長率成長至 27 億美元。

豬肉是全球消費量和產量不斷成長的肉類之一，推動了市場成長。隨著人口成長、城市化進程加快以及飲食習慣轉變，人們對動物蛋白的需求日益成長，畜牧業的擴張也使得保障豬群的健康和生產力成為重中之重。為了提高效率和產量，集約化養豬業更加重視預防性保健，疫苗在最大限度降低可能影響動物存活和經濟效益的疾病風險方面發揮關鍵作用。此外，在嚴重依賴豬肉的地區，糧食安全仍然是一個緊迫的問題，因此透過疫苗接種進行疾病預防對於維持穩定的供應鏈、防止價格飆升以及保障這一關鍵蛋白質來源的供應至關重要。

去活化疫苗或去活化疫苗市佔率比57.6%，2024年市場規模達8.624億美元。這類疫苗因其安全性高、穩定性好、保存期限長而備受青睞，尤其適用於大規模疫苗接種項目，特別是冷鏈系統完善的地區。它們在預防常見豬病方面的可靠性確保了其在全球市場的持續需求。

2024年，病毒感染細分市場創造了9.906億美元的市場規模，預計到2034年將以6.3%的複合年成長率成長。此細分市場的成長主要得益於影響豬群的傳染性病毒疾病的高發生率及其造成的經濟損失，包括那些會導致繁殖障礙、生長遲緩和重大經濟損失的疾病。在豬群密度高的養殖場，病毒的高傳染性使得疫苗接種成為最有效的預防策略，從而維持了該細分市場的主導地位。

2024年北美豬疫苗市場規模為6.508億美元，預計到2034年將達到11億美元，2025年至2034年間的複合年成長率（CAGR）為5.6%。該地區的領先地位得益於先進的畜牧管理實踐、完善的獸醫保健基礎設施以及對優質豬肉的強勁需求。大型商業養豬場、傳染病的頻繁爆發以及領先的動物保健公司的存在，都推動了疫苗的普及，並鞏固了北美市場的主導地位。

全球豬疫苗市場的主要參與者包括 Addison Biological Laboratory、Bioveta、勃林格殷格翰、Ceva Sante Animale、科羅拉多血清公司、禮來動物保健公司、HIPRA SA、Indian Immunologicals、默克、Biogenesis Bago、Vaxxinova（EWEW集團）、維克和碩騰集團）、維克和碩騰集團。這些公司透過投資研發，開發針對新出現的病毒性和細菌性豬病的創新高效疫苗，從而鞏固其市場地位。他們透過策略合作、併購等方式拓展全球業務，同時提高供應鏈效率，確保關鍵地區的疫苗供應。此外，這些公司也致力於向養豬戶普及預防保健知識，最佳化冷鏈物流，並提供豬群健康監測計畫等加值服務。

目錄

第1章：方法論與範圍

第2章：執行概要

第3章：行業洞察

• 產業生態系分析
  • 供應商格局
  • 每個階段的價值增加
  • 影響價值鏈的因素
• 產業影響因素
  • 成長促進因素
    • 人畜共患病發生率上升
    • 畜牧業擴張與糧食安全問題
    • 疫苗技術的進步
    • 動物疾病爆發日益增多
  • 產業陷阱與挑戰
    • 研發成本高且開發週期長
    • 冷鏈基礎設施的限制
    • 監理複雜性和核准延誤
  • 市場機遇
    • mRNA和下一代平台的應用
    • 耐熱疫苗的研發
    • 聯合疫苗創新
• 成長潛力分析
• 監管環境
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
• 疫苗技術發展與創新
  • 當前技術趨勢
  • 新興技術
• 未來市場趨勢
• 定價分析
• 專利分析
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
  • 全球的
  • 北美洲
  • 歐洲
  • 亞太地區
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 擴張計劃

第5章：市場估算與預測：依類型分類，2021-2034年

• 主要趨勢
• 減毒活疫苗
• 去活化疫苗
• 病毒載體疫苗
• mRNA疫苗
• 其他疫苗

第6章：市場估算與預測：依應用領域分類，2021-2034年

• 主要趨勢
• 細菌感染
• 病毒感染
• 寄生蟲感染
• 其他應用

第7章：市場估計與預測：依給藥途徑分類，2021-2034年

• 主要趨勢
• 注射疫苗
• 口服疫苗
• 浸泡/噴灑疫苗

第8章：市場估算與預測：依配銷通路分類，2021-2034年

• 主要趨勢
• 獸醫院藥房
• 零售藥局
• 電子商務

第9章：市場估計與預測：依地區分類，2021-2034年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 阿拉伯聯合大公國

第10章：公司簡介

• Addison Biological Laboratory
• Bioveta, as
• Boehringer Ingelheim
• Ceva Sante Animale
• Colorado Serum Company
• Elanco Animal Health Incorporated
• HIPRA SA
• Indian Immunologicals
• Merck
• biogenesis Bago
• Vaxxinova (EW Group)
• Virbac
• Zoetis

The Global Swine Vaccines Market was valued at USD 1.5 billion in 2024 and is estimated to grow at a CAGR of 6.1% to reach USD 2.7 billion by 2034.

Market growth is driven by the rising global consumption and production of pork, one of the most widely consumed meats worldwide. Ensuring the health and productivity of swine herds has become a priority as the livestock industry expands to meet the growing demand for animal protein, fueled by rising populations, urbanization, and shifting dietary preferences. Intensification of swine production for higher efficiency and yield emphasizes preventive healthcare, with vaccines playing a critical role in minimizing disease risks that can impact animal survival and economic returns. Additionally, food security remains a pressing concern in regions heavily reliant on pork, making disease prevention through vaccination crucial to maintain stable supply chains, prevent price spikes, and safeguard the availability of this key protein source.

The inactivated or killed vaccines segment held a 57.6% share and was valued at USD 862.4 million in 2024. These vaccines are preferred for their proven safety, stability, and long shelf life, making them ideal for large-scale vaccination programs, particularly in areas with established cold chain systems. Their reliability in preventing common swine diseases ensures ongoing demand across global markets.

The viral infections segment generated USD 990.6 million in 2024 and is expected to grow at a CAGR of 6.3% through 2034. This segment's growth is driven by the high prevalence and economic impact of contagious viral diseases that affect swine, including those that cause reproductive failures, growth retardation, and significant financial losses. High transmissibility in densely populated farms makes vaccination the most effective preventive strategy, sustaining this segment's market dominance.

North America Swine Vaccines Market generated USD 650.8 million in 2024 and is expected to reach USD 1.1 billion by 2034, growing at a CAGR of 5.6% between 2025 and 2034. The region's leadership is supported by advanced livestock management practices, robust veterinary healthcare infrastructure, and strong demand for high-quality pork. Major commercial swine operations, frequent outbreaks of contagious diseases, and the presence of leading animal health companies drive vaccine adoption and reinforce North America's dominant market position.

Key players operating in the Global Swine Vaccines Market include Addison Biological Laboratory, Bioveta, a.s., Boehringer Ingelheim, Ceva Sante Animale, Colorado Serum Company, Elanco Animal Health Incorporated, HIPRA S.A., Indian Immunologicals, Merck, biogenesis Bago, Vaxxinova (EW Group), Virbac, and Zoetis. Companies in the Swine Vaccines Market strengthen their presence by investing in research and development to create innovative, high-efficacy vaccines targeting emerging viral and bacterial swine diseases. They expand global reach through strategic partnerships, mergers, and acquisitions, while improving supply chain efficiency to ensure vaccine availability in key regions. Firms focus on educating swine producers about preventive healthcare benefits, optimizing cold chain logistics, and offering value-added services such as herd health monitoring programs.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Application trends
  • 2.2.4 Route of administration trends
  • 2.2.5 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of zoonotic diseases
    • 3.2.1.2 Expanding livestock industry and food security concerns
    • 3.2.1.3 Advancements in vaccine technology
    • 3.2.1.4 Increasing outbreaks of animal diseases
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High R&D costs & long development timelines
    • 3.2.2.2 Cold chain infrastructure limitations
    • 3.2.2.3 Regulatory complexity & approval delays
  • 3.2.3 Market opportunities
    • 3.2.3.1 mRNA & next-generation platform adoption
    • 3.2.3.2 Thermostable vaccine development
    • 3.2.3.3 Combination vaccine innovation
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Vaccine technology evolution and innovation
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends
• 3.7 Pricing analysis
• 3.8 Patent analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Live attenuated vaccines
• 5.3 Inactivated/killed vaccines
• 5.4 Viral vector vaccines
• 5.5 mRNA vaccines
• 5.6 Other vaccines

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Bacterial infections
• 6.3 Viral infections
• 6.4 Parasitic infections
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Injection vaccines
• 7.3 Oral vaccines
• 7.4 Immersion/spray vaccines

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 UAE

Chapter 10 Company Profiles

• 10.1 Addison Biological Laboratory
• 10.2 Bioveta, a.s.
• 10.3 Boehringer Ingelheim
• 10.4 Ceva Sante Animale
• 10.5 Colorado Serum Company
• 10.6 Elanco Animal Health Incorporated
• 10.7 HIPRA S.A.
• 10.8 Indian Immunologicals
• 10.9 Merck
• 10.10 biogenesis Bago
• 10.11 Vaxxinova (EW Group)
• 10.12 Virbac
• 10.13 Zoetis